TY - JOUR
T1 - Chemotherapeutic dose intensification for treatment of malignant brain tumors
T2 - Recent developments and future directions
AU - Kraemer, Dale F.
AU - Fortin, David
AU - Neuwelt, Edward A.
N1 - Funding Information:
Financial support for this work was provided by a Veterans Affairs Merit Review Grant and by National Institute of Health grants CA31770 from the National Cancer Institute and NS33618 and NS34608 from the National Institute of Neurological Disorders and Stroke (Edward A. Neuwelt, principal investigator).
Publisher Copyright:
© 2002, Current Science Inc.
PY - 2002/6
Y1 - 2002/6
N2 - Despite a large amount of research on malignant brain tumors over the past 70 years, the prognosis for most tumor types is poor. One current focus of research is increasing dose intensity of chemotherapeutic agents. Various ways to increase dose intensity include high-dose chemotherapy followed by stem cell rescue (eg, bone marrow transplant), blood-brain barrier disruption or use of RMP7 to increase transvascular drug delivery, local delivery of chemotherapeutic agents (convection enhancement or clysis, antibody conjugates, and biodegradable polymers), chemoprotective agents, and tumor sensitizers. Improved identification of patients likely to respond to a given regimen may also increase the effectiveness of chemotherapy. We also discuss approaches to improve the design of nonrandomized trials by identifying and controlling potential confounding variables. This will improve the quality of individual studies and perhaps the comparability across studies.
AB - Despite a large amount of research on malignant brain tumors over the past 70 years, the prognosis for most tumor types is poor. One current focus of research is increasing dose intensity of chemotherapeutic agents. Various ways to increase dose intensity include high-dose chemotherapy followed by stem cell rescue (eg, bone marrow transplant), blood-brain barrier disruption or use of RMP7 to increase transvascular drug delivery, local delivery of chemotherapeutic agents (convection enhancement or clysis, antibody conjugates, and biodegradable polymers), chemoprotective agents, and tumor sensitizers. Improved identification of patients likely to respond to a given regimen may also increase the effectiveness of chemotherapy. We also discuss approaches to improve the design of nonrandomized trials by identifying and controlling potential confounding variables. This will improve the quality of individual studies and perhaps the comparability across studies.
KW - Cytosine Deaminase
KW - Historic Control Patient
KW - Increase Dose Intensity
KW - Malignant Brain Tumor
KW - Stem Cell Rescue
UR - http://www.scopus.com/inward/record.url?scp=0036582336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036582336&partnerID=8YFLogxK
U2 - 10.1007/s11910-002-0080-8
DO - 10.1007/s11910-002-0080-8
M3 - Article
C2 - 11937000
AN - SCOPUS:0036582336
SN - 1528-4042
VL - 2
SP - 216
EP - 224
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 3
ER -